NSE filing, NSE: ALKEM. Summary written from the filing by ALFA Finder's alert engine.
Alkem Laboratories Ltd: key numbers
- Share price
- ₹5,070.00
- Market cap
- ₹60,619 Cr
- Revenue (annual)
- ₹14,712 Cr
- Net profit (annual)
- ₹2,302 Cr
- P/E (TTM)
- 28.1×Sector 46.1×
- Promoter holding
- 49.70%+0.00% QoQ
- FII holding
- 10.32%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alkem Laboratories Ltd
All →Alkem Laboratories Legal & Regulatory
Alkem Laboratories has initiated a forensic audit by Grant Thornton Bharat LLP following alleged misappropriation of funds by a former employee.
Alkem Laboratories Other Announcement
Alkem Laboratories Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements. This document details the company's equity structure.
Alkem Laboratories Management Change
Alkem Laboratories appointed Laxmikant Tiwari and Nilesh Vartak as Senior Management Personnel effective 12 October 2026. The appointments strengthen pharmaceutical operations and supply chain leadership.
Alkem Laboratories Management Change
Alkem Laboratories CFO Nitin Agrawal resigned effective 30 September 2026 for new opportunities. He was also a Key Managerial Personnel of the company.
Alkem Laboratories Debt & Borrowing: ₹593.5 Cr
Alkem Laboratories issued a Corporate Guarantee of Euro 54.45 Million to HSBC UK Bank for a Euro 49.5 Million term loan taken by its subsidiary, Occlutech Holding.
- Value
- ₹593.5 Cr
Alkem Laboratories Product Launch
Alkem launches NeuCeno (cenobamate), an anti-seizure medication for partial-onset seizures in adults, for the first time in India. The once-daily drug is available in six tablet strengths.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.